Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1992-11-5
pubmed:abstractText
Despite the many imaging techniques available to evaluate the liver, deficiencies persist. The choice of the optimal method is still controversial, with competing issues of safety, efficacy, and cost. Numerous strategies to improve the results of liver imaging have been pursued, including the application of tissue-targeted contrast agents to magnetic resonance imaging (MRI). Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate) (Mn-DPDP) is one of several recently developed hepatobiliary agents, targeted to functioning hepatocytes. The Mn-DPDP-enhanced MRI has demonstrated promise in the clinical trials. Contrast-to-noise measurements have shown favorable results for Mn-DPDP-enhanced MR compared to non-enhanced T1- and T2-weighted images. The ability to characterize tumors of hepatocellular origin and an improved capability for lesion detection have also been demonstrated. Furthermore, the prolonged enhancement obtained with Mn-DPDP has extended the time during which effective contrast is maintained. Importantly, no clinically significant adverse events have been demonstrated. This report will detail the clinical experience with Mn-DPDP-enhanced MRI of the abdomen.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0899-9422
pubmed:author
pubmed:issnType
Print
pubmed:volume
8
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
156-68
pubmed:dateRevised
2004-11-17
pubmed:meshHeading
pubmed:year
1992
pubmed:articleTitle
Manganese (II) N,N'-dipyridoxylethylenediamine-N,N'-diacetate 5,5'-bis(phosphate): clinical experience with a new contrast agent.
pubmed:affiliation
Department of Magnetic Resonance Imaging, New York University Medical Center, NY 10016.
pubmed:publicationType
Journal Article